Pancreatic and colorectal cancers are notoriously difficult to treat and often return after initial therapy. However, a new ready-to-use vaccine, ELI-002 2P, is offering renewed hope after showing encouraging results in a recent clinical trial.
Innovative Vaccine Targets KRAS Mutations with Precision Delivery System
Created by scientists from various U.S. institutions, the vaccine targets mutations in the KRAS gene—mutations found in 93% of pancreatic cancers and 50% of colorectal cancers.
The treatment uses a specialized delivery system that directs the vaccine’s active component to the lymph nodes, aiming to engage specific areas of the immune system where diverse immune cells are concentrated.
“This represents a significant breakthrough for patients with KRAS-driven cancers, especially pancreatic cancer, where recurrence after standard treatment is nearly inevitable and treatment options are scarce,” says medical oncologist Zev Wainberg from the University of California, Los Angeles.
The vaccine was trialed in 20 individuals recovering from pancreatic cancer and five recovering from colorectal cancer. All participants had undergone surgery to remove tumors but showed indications in follow-up tests that the cancer was likely to return.
Strong Immune Response and Tumor Clearance Observed After Vaccination
Following a series of vaccine injections, the outcomes were encouraging: 84% of participants developed T cells specifically targeting the mutant KRAS gene, while 24% showed complete tumor clearance.
Among the 24 individuals who mounted the strongest immune responses, 17 remained cancer-free at their most recent follow-up—nearly 20 months later on average. Given the aggressive nature of these cancers, these results are notable.
“We found that patients with strong immune responses to the vaccine stayed disease-free and lived significantly longer than anticipated,” says Wainberg.
Among all study participants, the median relapse-free survival was 16.33 months, and the median overall survival reached 28.94 months—both significantly longer than typically seen with these types of cancers.
Off-the-Shelf Vaccine Offers Hope for Faster, Accessible Treatment
What adds to the promise of ELI-002 2P is that it’s an “off-the-shelf” vaccine, meaning it’s a ready-made treatment that doesn’t require individual customization—a process that usually demands time and specialized resources.
While ongoing trials and tests will thoroughly evaluate the vaccine’s risks and benefits, the high recurrence and mortality rates of pancreatic and colorectal cancers make these early findings especially promising—indicating the vaccine could significantly extend patients’ healthy years.
Researchers also observed encouraging signs that the vaccine may help the immune system recognize and combat other cancer-related mutations, indicating its potential for broader application in future cancer treatments.
“KRAS has historically been one of the toughest targets in cancer treatment,” says Wainberg. “This study demonstrates that the ELI-002 2P vaccine can safely and effectively train the immune system to identify and attack cancer-causing mutations.”
“It presents a promising strategy for producing targeted, long-lasting immune responses—without the high cost or complexity of fully personalized vaccines.”
Read the original article on: Sciencealert
Read more: Lab-Made Artificial Life Can Grow and Divide Similarly to Natural Bacteria